Glenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentation
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals reported Q1 FY26 consolidated revenue of Rs. 32,644 Mn, up just 0.6% YoY, with EBITDA of Rs. 5,805 Mn at a margin of 17.8% (down from 18.1% YoY) and Adjusted PAT margin at 9.6% vs 10.5% YoY. The India business grew 3.7% YoY to Rs. 12,399 Mn, while the US business recovered with 8.9% QoQ growth driven by 3 new launches including generic Adderall. Europe and Emerging Markets declined YoY (-4% and +0.2%), but management guided for double-digit growth from Q2 FY26 onwards. Key highlights include the IGI-AbbVie global licensing deal for the ISB 2001 oncology asset, RYALTRIS commercialization in 45+ markets with 90+ filings, and a pipeline of 52 ANDAs pending US approval (including 24 Para IVs).
Flat top-line growth and mild YoY margin slippage point to near-term earnings pressure, but the US recovery, innovation pipeline, and management's confidence in double-digit growth resuming from Q2 may provide support to sentiment. Stock reaction will likely hinge on whether the pipeline catalysts (respiratory ANDAs in H2, AbbVie-partnered oncology asset) gain traction.